National Institute of Allergy and Infectious Diseases Archives
Feb. 24, 2022—A Vanderbilt study will explore the neurologic and psychiatric complications of flu and evaluate adverse effects of the antiviral treatment oseltamivir, also known by the brand name Tamiflu.
May. 12, 2021—Anthony Fauci, MD, chief medical adviser to President Joe Biden’s administration and director of the National Institute of Allergy and Infectious Diseases (NIAID), recently met virtually with students of Vanderbilt University School of Medicine’s Master of Public Health (MPH) program to answer questions about lessons learned during the pandemic and to share career advice.
Feb. 11, 2021—Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have received renewal of a major federal grant to continue their collaboration to test and develop new treatments and vaccines against HIV/AIDS — and now COVID-19.
Dec. 17, 2020—Vanderbilt University Medical Center has a new weapon in the fight against COVID-19 — an investigational antibody treatment approved last month for emergency use in COVID-19 outpatients at high risk of developing severe disease or requiring hospital care.
Jun. 4, 2020—The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.